Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. ERYTECH Pharma S.A.
  6. Financials
    ERYP   FR0011471135

ERYTECH PHARMA S.A.

(ERYP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization1 11212013963,1--
Entreprise Value (EV)1 -20,261,112279,2123119
P/E ratio -2,93x-1,92x-1,78x-0,73x-1,12x-16,7x
Yield ------
Capitalization / Revenue 25,2x22,7x37,4x9,37x3,48x1,32x
EV / Revenue -4,55x11,6x32,8x11,8x6,77x2,49x
EV / EBITDA 0,47x-1,02x-1,91x-1,31x-3,11x-59,5x
Price to Book 0,77x1,40x4,93x-2,76x-0,89x-1,61x
Nbr of stocks (in thousands) 17 93817 93819 56227 921--
Reference price (EUR) 6,256,707,112,262,262,26
Announcement Date 03/11/201903/16/202003/08/2021---
1 EUR in Million
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales1 4,455,283,726,7418,147,7
EBITDA1 -42,8-59,9-63,8-60,6-39,5-2,00
Operating profit (EBIT)1 -43,6-64,1-68,8-61,2-53,8-21,9
Operating Margin -981%-1 213%-1 851%-908%-297%-45,9%
Pre-Tax Profit (EBT)1 -38,2-62,7-73,3-57,8-64,5-47,0
Net income1 -38,2-62,7-73,3-61,2-56,3-24,4
Net margin -860%-1 186%-1 971%-909%-310%-51,1%
EPS2 -2,13-3,49-3,99-3,10-2,01-0,14
Dividend per Share ------
Announcement Date 03/11/201903/16/202003/08/2021---
1 EUR in Million
2 EUR
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q1 2021 Q2 2021 S1 2021 Q3 2021 Q4 2021 S2
Net sales1 1,440,832,271,251,250,90
EBITDA ---26,5---24,2
Operating profit (EBIT)1 -13,2-15,7-29,0-15,5-14,1-27,0
Operating Margin -920%-1 894%-1 276%-1 237%-1 131%-3 000%
Pre-Tax Profit (EBT)1 -11,9-16,0-28,0-15,4-14,0-30,7
Net income1 -11,9-16,0-28,0-15,4-14,0-30,7
Net margin -830%-1 929%-1 231%-1 228%-1 123%-3 411%
EPS ---1,22---1,10
Dividend per Share ------
Announcement Date 05/04/202109/20/202109/20/2021---
1 EUR in Million
Previous periodNext period
Balance Sheet Analysis
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt1 ---16,159,855,8
Net Cash position1 13259,117,0---
Leverage (Debt / EBITDA) 3,09x0,99x0,27x-0,27x-1,51x-27,9x
Free Cash Flow1 -53,5-63,4-52,9-75,1-43,84,00
ROE (Net Profit / Equities) -23,4%-54,2%-131%---
Shareholders' equity1 16411656,0---
ROA (Net Profit / Asset) ------
Assets1 ------
Book Value Per Share2 8,124,771,44-0,82-2,54-1,40
Cash Flow per Share -2,19-2,41----
Capex1 14,220,11,141,401,801,35
Capex / Sales 320%381%30,6%20,8%9,92%2,83%
Announcement Date 03/11/201903/16/202003/08/2021---
1 EUR in Million
2 EUR
Key data
Capitalization (EUR) 63 101 509
Capitalization (USD) 71 228 704
Net sales (EUR) 3 718 000
Net sales (USD) 4 199 853
Number of employees 196
Sales / Employee (EUR) 18 969
Sales / Employee (USD) 21 428
Free-Float 67,5%
Free-Float capitalization (EUR) 42 567 426
Free-Float capitalization (USD) 48 049 922
Avg. Exchange 20 sessions (EUR) 1 072 896
Avg. Exchange 20 sessions (USD) 1 211 943
Average Daily Capital Traded 1,70%
EPS & Dividend